Table 10.
Effect on final weight loss, off-label patients—adjusted analyses.
| Young Adults (19–25 years old) | Adolescents (13–18 years old) | Children (5–12 years old) | ||||
|---|---|---|---|---|---|---|
| ‡N = 376 medication instances | ‡N = 168 medication instances | ‡N = 27 medication instances | ||||
| %TBW (95% CI) | P-value | ΔBMIz (95% CI) | P-value | ΔBMIz (95% CI) | P-value | |
| Medication* | ||||||
| Metformin | −1.68 (−2.8–0.6) | 0.003 | −0.02 (0.0–0.0) | 0.03 | 0.01 (−0.1–0.1) | >0.1 |
| Topiramate | 1.31 (0.3–2.3) | 0.01 | −0.03 (−0.1–0.0) | >0.1 | −0.01 (−0.1–0.1) | >0.1 |
| Bupropion | −6.79 (−13.2–0.4) | 0.04 | — | — | — | — |
| Phentermine | 1.37 (0.0–2.8) | 0.06 | 0.15 (0.1–0.2) | <0.001 | — | — |
| Zonisamide | −2.37 (−7.7–3.0) | >0.1 | — | — | — | — |
| Naltrexone | 2.39 (0.3–4.4) | 0.02 | — | — | — | — |
| Orlistat | −1.77 (−4.2–0.6) | >0.1 | — | — | — | — |
| Obesity class | ||||||
| Overweight | ref | — | ref | — | ref | — |
| Class I (mild) | 5.86 (2.0–9.8) | 0.003 | 0.07 (−0.1–0.3) | >0.1 | — | — |
| Class II (moderate) | 8.45 (4.8–12.1) | <0.001 | 0.10 (−0.1–0.3) | >0.1 | −0.05 (−0.3–0.2) | >0.1 |
| Class III (severe) | 7.74 (4.1–11.3) | <0.001 | 0.08 (−0.1–0.3) | >0.1 | 0.01 (−0.2–0.2) | >0.1 |
| Age at med initiation, years | 0.18 (−0.2–0.6) | >0.1 | 0.01 (0.0–0.0) | >0.1 | −0.02 (−0.1–0.0) | >0.1 |
| Female sex | −0.83 (−3.0–1.3) | >0.1 | −0.01 (−0.1–0.0) | >0.1 | −0.02 (−0.3–0.3) | >0.1 |
| Race | ||||||
| White | ref | — | ref | — | ref | — |
| Black | −2.64 (−4.9–0.4) | 0.02 | 0.09 (0.0–0.2) | 0.005 | −0.28 (−0.5–0.1) | 0.01 |
| Hispanic | −1.53 (−3.6–0.6) | >0.1 | 0.04 (0.0–0.1) | >0.1 | −0.11 (−0.4–0.2) | >0.1 |
| Asian | −1.62 (−7.8–4.5) | >0.1 | 0.05 (0.0–0.1) | >0.1 | — | — |
| Insurance | ||||||
| Private | ref | — | ref | — | ref | — |
| Medicaid | 0.51 (−1.1–2.1) | >0.1 | 0.03 (0.0–0.1) | >0.1 | 0.08 (−0.1–0.3) | >0.1 |
| Self-pay | −1.72 (−10.4–7.0) | >0.1 | −0.03 (−0.1–0.0) | >0.1 | — | — |
| Obesity-related illnesses, N | ||||||
| 0 | ref | — | ref | — | ref | — |
| 1–2 | −0.97 (−4.5–2.5) | >0.1 | 0.01 (−0.1–0.1) | >0.1 | −0.32 (−0.8–0.2) | >0.1 |
| 3–4 | 0.42 (−2.9–3.7) | >0.1 | −0.01 (−0.1–0.1) | >0.1 | −0.40 (−0.7–0.1) | 0.02 |
| 5–6 | −1.36 (−4.8–2.1) | >0.1 | −0.10 (−0.2–0.0) | 0.05 | — | — |
| ≥6 | 1.51 (−3.3–6.3) | >0.1 | −0.22 (−0.6–0.2) | >0.1 | −0.39 (−0.8–0.0) | 0.06 |
*
Coefficient indicates difference between respective medication and the overall frequency-weighted mean.
‡
N, patients with both pre-medication and post-medication weights recorded in chart. ref, reference group. Bold and italic value represents means-statistically significant.